Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06586671 · ClinicalTrials.gov registry record · Phase 1
A Study to Compare Forms of Nemtabrutinib (MK-1026) in Healthy Adult Participants (MK-1026-007)
A Phase 1 study of Hematological Malignancy, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06586671: Completed Phase 1 study of Hematological Malignancy, sponsored by Merck Sharp & Dohme.
NCT06586671 is a Phase 1 study of Hematological Malignancy that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 40 participants, below the 117-participant average among 9 other Hematological Malignancy trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06586671, a Phase 1 study of Hematological Malignancy, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of the study is to measure and compare the levels of nemtabrutinib in the blood after taking different forms of nemtabrutinib orally on an empty stomach (fasted) to see if they are the same or different.
Primary Outcome
Blood samples will be collected to determine the AUC0-inf of nemtabrutinib.
Conditions Studied
Interventions
- DRUG Nemtabrutinib
Study Locations (1)
Florida
- QPS-MRA, LLC-Early Phase (Site 0002) - South Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-08-28 |
| Est. Completion | 2023-11-13 |
| Phase | Phase 1 |
What the finished NCT06586671 record still lists
NCT06586671 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 117-participant average among 9 other Hematological Malignancy trials with a reported enrollment target (66% lower).
The record links to 1 condition, with Hematological Malignancy appearing as the primary indexed condition, and to 1 intervention - of which Nemtabrutinib is the first listed.
NCT06586671 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06586671 about?
NCT06586671 is a clinical study titled "A Study to Compare Forms of Nemtabrutinib (MK-1026) in Healthy Adult Participants (MK-1026-007)". The goal of the study is to measure and compare the levels of nemtabrutinib in the blood after taking different forms of nemtabrutinib orally on an empty stomach (fasted) to see if they are the same or different.
What is the current status of trial NCT06586671?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2023-08-28. Estimated completion is 2023-11-13.
What conditions does trial NCT06586671 study?
This clinical trial studies the following conditions: Hematological Malignancy.
What interventions are being tested in trial NCT06586671?
The interventions under investigation include: Nemtabrutinib (DRUG).
Who is sponsoring clinical trial NCT06586671?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06586671 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematological Malignancy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06586671's enrollment target sits among peer trials
40 7th of 9 higher than 3 of 9 other Hematological Malignancy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hematological Malignancy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances
RECRUITING · Phase 1
-
Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies
COMPLETED · Phase 1
-
Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia
RECRUITING · Phase 2
-
HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib
RECRUITING · Phase 2
-
A Pilot Prospective Clinical Trial Using Remote Monitoring for Cancer Patients Undergoing Outpatient Chemotherapy
RECRUITING
-
A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI